Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
S49076 . HCl
114
CHF
CHF 114.00
In stock
SYN-1217-M0011 mgCHF 114.00
SYN-1217-M0055 mgCHF 213.00
SYN-1217-M01010 mgCHF 355.00
SYN-1217-M05050 mgCHF 1'064.00
SYN-1217-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | S-49076 . HCl; (Z)-3-((3-((4-(Morpholinomethyl)-1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)methyl)thiazolidine-2,4-dione hydrochloride |
| Product Type | Chemical |
| Properties | |
| Formula | C22H23ClN4O4S |
| MW | 475.0 |
| CAS | 1265965-19-2 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: MET, AXL, FGFR | Kinase Group: TK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | FPSAJUOIYZSJJA-NAIZSXBXSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
S49076 is a novel, potent inhibitor of MET, AXL/MER and FGFR1/2/3. It can potently block cellular phosphorylation of MET, AXL and FGFRs and inhibit downstream signalling in vitro and in vivo. S49076 can inhibit the proliferation of MET- and FGFR2-dependent gastric cancer cells, block MET-driven migration of lung carcinoma cells, and inhibit colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL. S49076 has also been shown to cause tumour growth arrest in bevacizumab-resistant tumours in xenograft models.
Product References
- S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab: M.F. Burbridge, et al.; Mol. Cancer Ther. 12, 1749 (2013)
Related Products
